These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 24006142)
41. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis. Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772 [No Abstract] [Full Text] [Related]
42. Myasthenia gravis with antibodies to MuSK: an update. Evoli A; Alboini PE; Damato V; Iorio R; Provenzano C; Bartoccioni E; Marino M Ann N Y Acad Sci; 2018 Jan; 1412(1):82-89. PubMed ID: 29266255 [TBL] [Abstract][Full Text] [Related]
43. Use of rituximab in muscle-specific tyrosine kinase antibody-positive myasthenia gravis: Preliminary observations from a tertiary care center in Northern India. Sachdeva J; Mahesh KV; Shree R; Jain G; Kapila AT; Shashikala TP; Goyal MK; Modi M; Lal V Indian J Pharmacol; 2020; 52(1):49-52. PubMed ID: 32201447 [TBL] [Abstract][Full Text] [Related]
44. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients. Illa I; Diaz-Manera J; Rojas-Garcia R; Pradas J; Rey A; Blesa R; Juarez C; Gallardo E J Neuroimmunol; 2008 Sep; 201-202():90-4. PubMed ID: 18653247 [TBL] [Abstract][Full Text] [Related]
45. Reversible tongue muscle atrophy accelerated by early initiation of immunotherapy in anti-MuSK myasthenia gravis: A case report. Kitamura E; Takiyama Y; Nakamura M; Iizuka T; Nishiyama K J Neurol Sci; 2016 Jan; 360():10-2. PubMed ID: 26723963 [No Abstract] [Full Text] [Related]
46. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. Topakian R; Zimprich F; Iglseder S; Embacher N; Guger M; Stieglbauer K; Langenscheidt D; Rath J; Quasthoff S; Simschitz P; Wanschitz J; Windisch D; Müller P; Oel D; Schustereder G; Einsiedler S; Eggers C; Löscher W J Neurol; 2019 Mar; 266(3):699-706. PubMed ID: 30649616 [TBL] [Abstract][Full Text] [Related]
47. [B-cell-depletion therapy in systemic autoinmune diseases. Recommendations for use in clinical practice]. Ramos-Casals M; Díaz-Lagares C; Khamashta MA; Med Clin (Barc); 2011 Mar; 136(6):257-63. PubMed ID: 20627323 [No Abstract] [Full Text] [Related]
48. Rituximab in the management of refractory myasthenia gravis. Zebardast N; Patwa HS; Novella SP; Goldstein JM Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027 [TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis. Li T; Zhang GQ; Li Y; Dong SA; Wang N; Yi M; Qi Y; Zhai H; Yang L; Shi FD; Yang CS J Clin Neurosci; 2021 Mar; 85():6-12. PubMed ID: 33581791 [TBL] [Abstract][Full Text] [Related]
50. Rituximab in AChR subtype of myasthenia gravis: systematic review. Di Stefano V; Lupica A; Rispoli MG; Di Muzio A; Brighina F; Rodolico C J Neurol Neurosurg Psychiatry; 2020 Apr; 91(4):392-395. PubMed ID: 32098874 [TBL] [Abstract][Full Text] [Related]
52. Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody-positive myasthenia gravis: response to cyclophosphamide and rituximab treatment. Lau AY; Chan AY; Mok VC Hong Kong Med J; 2011 Feb; 17(1):77-9. PubMed ID: 21282832 [TBL] [Abstract][Full Text] [Related]
53. [Novel immunomodulatory therapies in myasthenia gravis]. Sukockiené E; Théaudin M; Loser V; Staedler K; Lalive PH; Lascano AM Rev Med Suisse; 2024 Apr; 20(871):848-851. PubMed ID: 38665106 [TBL] [Abstract][Full Text] [Related]